We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Name | Symbol | Market | Type |
|---|---|---|---|
| Roche Holdings Ltd AG (QX) | USOTC:RHHBY | OTCMarkets | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.07 | -0.23% | 29.75 | 29.55 | 30.50 | 30.05 | 29.53 | 29.80 | 5,444,214 | 21:57:01 |
From May 2019 to May 2024
By Michael Dabaie
Roche Group's (RHHBY) Genentech said the U.S. Food and Drug Administration approved Venclexta in combination with Gazyva for the treatment of people with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma.
Venclexta is being developed by AbbVie Inc. (ABBV) and Genentech.
The approval is based on the results of the randomized Phase III CLL14 study. Fixed 12-month treatment with Venclexta plus Gazyva significantly reduced the risk of disease progression or death by 67% compared to a current standard of care, Genentech said.
Write to Michael Dabaie at michael.dabaie@wsj.com
(END) Dow Jones Newswires
May 15, 2019 15:15 ET (19:15 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
1 Year Roche (QX) Chart |
1 Month Roche (QX) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
